학술논문

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
Document Type
Journal
Source
JOURNAL FOR IMMUNOTHERAPY OF CANCER; MAR 2024, 12 3, pe008638 11p.
Subject
Language
English
ISSN
20511426